FLULAVAL, FLULAVAL QUADRIVALENT Drug Profile

Summary for Tradename: FLULAVAL, FLULAVAL QUADRIVALENT

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for FLULAVAL, FLULAVAL QUADRIVALENT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for FLULAVAL, FLULAVAL QUADRIVALENT Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for FLULAVAL, FLULAVAL QUADRIVALENT Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	10,004,803	2036-10-12	Patent claims search
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	10,030,231	2034-01-23	Patent claims search
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	10,034,931	2034-09-23	Patent claims search
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	10,047,116	2040-01-30	Patent claims search
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	10,059,925	2035-08-03	Patent claims search
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	10,124,056	2034-08-18	Patent claims search

FLULAVAL, FLULAVAL QUADRIVALENT Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of FluLaval and FluLaval Quadrivalent

Introduction to FluLaval and FluLaval Quadrivalent

FluLaval and FluLaval Quadrivalent are prominent influenza vaccines developed by GlaxoSmithKline (GSK), a leading player in the global pharmaceutical industry. These vaccines are designed to protect against influenza, a highly contagious respiratory illness.

Market Size and Growth

The influenza vaccines market, which includes FluLaval and FluLaval Quadrivalent, is experiencing significant growth. As of 2024, the U.S. influenza vaccines market is valued at approximately $4.78 billion and is projected to reach $9.66 billion by 2033, with a compound annual growth rate (CAGR) of about 8% from 2025 to 2033[1].

Globally, the influenza vaccine market was valued at $7.97 billion in 2023 and is expected to grow to $17.77 billion by 2032, with a CAGR of 9.6% from 2024 to 2032[2].

Segmentation and Dominance

The market is segmented based on valency, with the quadrivalent segment dominating due to its greater demand and broader protection against four strains of the influenza virus. FluLaval Quadrivalent, being a quadrivalent vaccine, benefits from this trend, contributing significantly to the market growth[2].

Key Market Drivers

Several factors are driving the growth of the influenza vaccines market, including:

Heightened Public Awareness

Increased public awareness of infectious diseases, particularly after the COVID-19 pandemic, has led to a higher demand for influenza vaccines[1].

Innovations in Vaccine Technology

Advancements in vaccine formulation and the launch of novel vaccines, such as the needle-free nasal influenza vaccine, are boosting market growth[1][2].

Government Initiatives

Government initiatives and recommendations from health organizations like the Centers for Disease Control and Prevention (CDC) are crucial in promoting vaccine accessibility and public health standards[1].

Market Challenges

Despite the positive trajectory, the market faces several challenges:

Supply Chain Issues

Stock shortages and logistical challenges can impact the availability and distribution of vaccines[3].

Regulatory Framework

Stringent regulatory requirements and the need for continuous clinical trials and approvals can slow down the introduction of new vaccines[1].

Pricing and Cost Analysis

The cost of FluLaval Quadrivalent varies but is generally around $182 for a supply of 5 milliliters, depending on the pharmacy and any available discounts or patient assistance programs[3].

Distribution and Demand Analysis

The distribution of influenza vaccines, including FluLaval Quadrivalent, is managed through various channels, including pharmacies, healthcare providers, and public health programs. The demand is high, especially during flu seasons, and is influenced by government immunization targets and public health campaigns[1].

Effectiveness and Safety

The effectiveness of influenza vaccines, such as FluLaval Quadrivalent, is a critical factor in their adoption. Studies have shown that these vaccines are safe and immunogenic, providing significant protection against influenza outbreaks[1].

Clinical Trials and Development

Several promising influenza vaccines are in clinical development, including those from key players like GSK, Sanofi Pasteur, and emerging companies such as Novavax and Moderna. These developments are expected to further enhance the market's growth potential[1].

Key Players and Emerging Companies

GSK, the manufacturer of FluLaval and FluLaval Quadrivalent, is one of the major players in the market. Other key players include Sanofi Pasteur, Seqirus, and AstraZeneca. Emerging companies like Novavax, Medicago, and Moderna are also making significant contributions to the market with their innovative vaccine technologies[1].

Regulatory Framework and Reimbursement Environment

The regulatory framework for influenza vaccines is stringent, with continuous monitoring and updates required to ensure safety and efficacy. The reimbursement environment varies by region but generally includes coverage under health insurance plans and patient assistance programs to make vaccines more accessible[1].

Merger and Acquisition Activities

The influenza vaccines market has seen several merger and acquisition activities, collaboration deals, and licensing agreements that have shaped the competitive landscape. These activities are expected to continue, driving innovation and market expansion[1].

Key Takeaways

• The U.S. influenza vaccines market, including FluLaval and FluLaval Quadrivalent, is valued at $4.78 billion in 2024 and is projected to reach $9.66 billion by 2033.
• The global market is expected to grow from $7.97 billion in 2023 to $17.77 billion by 2032.
• Quadrivalent vaccines, such as FluLaval Quadrivalent, dominate the market due to their broader protection.
• Key drivers include public awareness, vaccine technology innovations, and government initiatives.
• Challenges include supply chain issues and regulatory requirements.
• Pricing varies, but patient assistance programs and discounts are available.

Frequently Asked Questions (FAQs)

1. What is the current market value of the U.S. influenza vaccines market?

As of 2024, the U.S. influenza vaccines market is estimated to be valued at approximately $4.78 billion[1].

2. What is the projected growth rate of the global influenza vaccine market from 2024 to 2032?

The global influenza vaccine market is projected to grow at a CAGR of 9.6% from 2024 to 2032[2].

3. Why are quadrivalent vaccines dominating the market?

Quadrivalent vaccines, such as FluLaval Quadrivalent, dominate the market due to their greater demand and broader protection against four strains of the influenza virus[2].

4. What are the key factors driving the growth of the influenza vaccines market?

Key drivers include heightened public awareness of infectious diseases, innovations in vaccine technology, and government initiatives promoting vaccine accessibility[1].

5. How much does FluLaval Quadrivalent typically cost?

The cost of FluLaval Quadrivalent is around $182 for a supply of 5 milliliters, depending on the pharmacy and any available discounts or patient assistance programs[3].

Sources:

1. United States Influenza Vaccines Market Report 2025 - ResearchAndMarkets.com
2. Influenza Vaccine Market Size | Growth Analysis Report [2032] - Fortune Business Insights
3. FluLaval Quadrivalent Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com
4. Flu Vaccine Influenza Vaccine Market Size, Trends and Forecast - Market Research Intellect
5. Influenza Vaccines Market (Vaccine Type, Virus Type) - BioSpace - The Insight Partners